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Open access under CC BY license.Prokineticins are multifunctional secreted proteins that
were originally identified as regulators of intestinal
contraction but subsequently shown to affect vascular
function, hyperalgesia, spermatogenesis, neuronal
survival, circadian rhythm, nociception, feeding
behaviour, immune responses, haematopoiesis and
the development of the olfactory and gonadotropin-
releasing hormone systems. Their role in the reproduc-
tive tract is still not fully elucidated, although they are
reputed to increase microvascular permeability.
Expression of prokineticins and their receptors has been
reported in the ovary, uterus, placenta, testis and
prostate. Their expression has also been reported in
various pathologies of the reproductive tract, and future
studies will highlight whether inhibition of prokineticin
function in these pathologies would be a useful
therapeutic target.
Introduction
Prokineticins (PKs) are factors that have been recently
described and are involved in a wide array of functions in
different tissues through the activation of their cognate
receptors. Here, we first give a general background of the
structure and functions of PKs and then focus on the role of
PKs in reproduction.
PKs and their receptors
The PKs are two recently identified proteins with roles in
physiological and pathological conditions. The names PK1
and PK2 were assigned to these proteins by Li et al. [1] to
reflect their functions in inducing specific and potent con-
tractions on the smooth muscle of the gastrointestinal
tract. Subsequently, LeCouter et al. [2] described a growth
factor which induced a strong and reproducible mitogenic
response in endocrine gland-derived endothelial cells. The
similar effects induced by this protein and by vascular
endothelial growth factor (VEGF) led it to be named endo-
crine gland VEGF (EG-VEGF). Although there are several
similarities in the functions and control mechanisms of
VEGF and EG-VEGF, the two factors are structurally
unrelated. The amino acid sequences for PK1 andCorresponding author: Jabbour, H.N. (h.jabbour@hrsu.mrc.ac.uk).
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review, the term ‘PK1’ is used throughout.
PK1 is the human orthologue of a nontoxic protein
isolated from the venom of the black mamba (Dendroaspis
polylepis) and named venom protein A (VPRA) [3] or
mamba intestinal toxin 1 (MIT1), owing to its ability to
contract guinea pig ileum [4,5]. PK1 is 80% homologous to
VPRA/MIT1 and is a mature protein of 86 amino acids,
with a signal peptide of 19 amino acids. The gene that
encodes the PK1 precursor is located on human chromo-
some 1p21 [6] and is encoded by three exons [1,2]
(Figure 1).
PK2 is the human paralogue of PK1 and orthologue of a
protein isolated from skin secretions of the toad Bombina
variegata, known as Bv8 [7]. A splice variant of PK2 has
been described in human, mouse and bull testis, having an
arginine and lysine-rich insert of 21 amino acids after
residue 47. This led to the splice variant being called
‘Bv8-basic’ (Bv8-b) [8]. The PK2 precursor is located on
human chromosome 3p21.1 [6] and is encoded by four
exons, with the third exon being subject to alternative
splicing [9] (Figure 1).
PK1 and PK2 share 44% amino acid identity and also
share a common protein structure motif. They have a
conserved N-terminal sequence (AVITGA), which is essen-
tial for the activity of these proteins. Mutations to this
sequence, by insertion of a methionine preceding the N-
terminal alanine, substitution of the N-terminal alanine
with a methionine [10] or deletion of the first two amino
acids [11], produce PK receptor (PKR) antagonists.
Another feature of the PKs is the presence of ten conserved
cysteines, which are predicted to form five disulfide bonds
[1,12] (Figure 1). These disulfide bonds are predicted to
form a fold in the PK1 molecule similar to that formed in
the related proteins colipase, and Dickkopfs [12,13], which
is essential to activity because incorrect folding of recom-
binant proteins, mutation of the cysteines or substitution
of the cysteine-rich domain produces proteins that have no
activity at PKRs [10].
The PKs are the cognate ligands for two closely related
G-protein-coupled receptors (GPCRs), termed PKR1 and
PKR2, which share 85% amino acid identity and exhibit
the greatest differences in their N-terminal sequences
[14,15] (Figure 2). Their sequences are almost identical
in the transmembrane domains [16], suggesting that their.2006.12.002
Figure 1. Amino acid sequence comparison between human PK1 and PK2, and several putative orthologues. High sequence homology (shaded grey residues) among
species is observed. Ten highly conserved cysteines predicted to form five disulfide bonds are highlighted in solid boxes. In PK2, the residues highlighted in a dashed box
correspond to the extra amino acids present in a splice variant that results from alternative splicing of exon 3. Key: H, human (Homo sapiens); M, mouse (Mus musculus); R,
rat (Rattus norvegicus); C, chicken (Gallus gallus); MIT, black mamba (Dendroaspis polylepis); Fu, fugu (Takifugu rubripes); Bom, toad (Bombina variegata).
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molecule analogues will not discriminate between the
receptors, as is the case for PK1 and PK2. The affinity of
these factors for their receptors is similar, with PK2 show-
ing a moderately higher affinity for both receptors
(Table 1).
PKRs have been reported to couple either to Gi [17] or to
Gq [14,16] proteins. In adrenal cortex capillary endothelial
(ACE) cells, activation of the receptors has been shown to
be inhibited by pertussis toxin [17], suggesting Gi coupling.
By contrast, in transfected CHO cells activation of the
receptors has been shown to induce calcium mobilization
and phosphoinositide hydrolysis [14–16], suggesting Gq
coupling. Signalling through these receptors is linked to
phospholipase Cb activation and generation of diacylgly-
cerol and inositol phosphate, with potential downstream
activation of protein kinase C, extracellular-signal-
regulated kinases (ERK) 1 and 2, Akt and nitric oxide
synthase [14,17,18]. Activation of ERK 1 and 2 through
PK1–PKR1 binding has been demonstrated, by use of
specific inhibitors, to be important in PK1-induced pro-
liferation and migration of ACE cells [17].
Functions of PKs and their receptors
PKs were initially reported to be expressed in the
gastrointestinal tract, where they were shown directly to
stimulate contraction of the ileum longitudinal muscle of
guinea pigs [1]. However, the opposing effect of relaxation
through a nitric oxide-mediated mechanism has recently
been reported in the murine proximal colon [18]. Inwww.sciencedirect.comaddition, it has been reported that PK2 has no effect on
forestomach or colon contraction [19]. These findings
suggest that the intracellular milieu in different tissues
results in differential coupling and different phenotypic
effects.
PKs are also expressed in steroidogenic tissues, includ-
ing the testis [8,20], ovary [21,22], placenta [2,23] and
adrenal glands [17]. In these tissues, it has been shown
that PKs are involved in survival, proliferation, differen-
tiation and induction of fenestrae of capillary endothelial
cells [17]. The effect of PKs on endothelial cells seems to be
tissue specific. For example, and in contrast to VEGF, PKs
have no effect on endothelial cells derived from aorta,
umbilical vein or cornea [2].
A role for PKs has also been suggested in haematopoi-
esis and in regulation of the immune response [24,25]. PK2
is expressed in the bone marrow, as well as in peripheral
blood cells, particularly in monocytes, neutrophils and
dendritic cells [25], whereas PK1 is expressed in B and
T cells, and in inflamed tissues [24]. In vitro studies
suggest that PKs promote survival and differentiation of
the granulocytic and monocytic lineages. Moreover, the
expression of PKR1 and PKR2 in progenitor and mature
blood cells [25] supports further the proposed participation
of PKs in haematopoiesis and the immune response.
PK2 expression has been demonstrated in the central
nervous system, and a role in supporting neuronal survival
has been suggested [26]. In the suprachiasmatic nucleus
(SCN), PK2 exhibits a circadian oscillation profile [27,28].
It has been proposed that PK2 functions as a crucial SCN
Figure 2. (a) Schematic representation of human PKR1. Putative N-glycosylation (<), sulfation (^) and a disulfide bridge (_
Q
_) sites are indicated. Serine or threonine
residues occurring in putative protein kinase C (), protein kinase A (+) and casein kinase II () phosphorylation sites are also indicated. Residues in blue squares are the
ones highly conserved throughout the rhodopsin family of GPCRs. The highly conserved NPXXY motif in the seventh transmembrane domain of the rhodopsin-like GPCR
family is changed to NTXXF in PKRs; this could be relevant in terms of the dynamics of receptor internalization [52,53]. (b) Sequence alignment for human PKR1 and PKR2.
These receptors have 85% homology (depicted by shaded grey amino acids), with the greatest differences in their N-terminal sequences.
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rhythms [27,29]. PK2 is also expressed in the olfactory
bulb, where it is involved in neurogenesis. Studies in vitrowww.sciencedirect.comshowed PK2-induced migration of subventricular
zone-derived neuronal progenitors [30]. This is supported
by mouse knockout studies, in which PK2/ and PKR2/
Table 1. Binding affinities of PK1 and PK2 to PKR1 and PKR2, respectivelya
PKR1 PKR2
Kd (nM) Ki (nM) IC50 (nM) Kd (nM) Ki (nM) IC50 (nM)
PK1 12.3  4.2 66.3  30.1 27.6  8.2 1.8  0.1 31.6  13.7 52.2  16.4
PK2 1.4  0.5 5.1  1.0 4.5  0.8 2.0  0.7 5.9  1.3 6.4  1.3
Abbreviations: Kd, dissociation constant; Ki, inhibitory constant; IC50, inhibitory concentration 50%.
aValues reported by Lin, D.C. et al. [14], Soga, T. et al. [16] and Chen, J. et al. [54].
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Interestingly, PKR2 knockout mice also show severe atro-
phy of the reproductive system, including the testis, ovary,
uterus, vagina and mammary gland. Immunohistological
studies demonstrated an absence of gonadotropin-releas-
ing hormone (GnRH) neurones in the hypothalamus of
these animals, suggesting that activation of PKR2 is
required for the correct migration of these neurones from
the olfactory placode into the forebrain during develop-
ment [28]. The PKR2/ phenotype is strikingly similar to
the Kallmann syndrome (KS) in humans, and recently PK2
andPKR2mutationswere identified in several KS patients
[31].
PKs are also involved in nociceptive sensitization and
regulation of feeding behaviour. Administration of PK2
through several routes decreased the nociceptive threshold
to thermal and mechanical pain in rats [32]. In addition,
PKR1 knockout mice showed impaired nociceptive and
inflammatory pain sensation to noxious heat [33]. Intra-
cerebroventricular delivery of PK2, or its amphibian hom-
ologue Bv8, potently suppressed feeding in rats [34].
The role of PKs and their receptors in human
reproductive function
There are two levels at which PKs can modulate reproduc-
tive function. As discussed earlier, PKs have an important
role in the development of the GnRH system but they can
also function directly in reproductive organs.
Male reproductive function
PKs and their receptors are expressed in the testis and the
prostate. In the testis, PK1 is predominantly expressed in
testosterone-producing Leydig cells, whereas PK2 is
restricted to primary spermatocytes [8,20]. The PKRs
are expressed in vascular endothelial cells in the testis
[20]. Interestingly, in the mouse testis, PKR1 and PKR2
are expressed equally, whereas in the human testis, PKR1
is expressed at higher levels in comparison to PKR2 [20].
The exact role of each of these receptors and the implica-
tions of differential levels of expression remain to be
elucidated.
It has been proposed that PKs, through their cognate
receptors, function as regulators of proliferation and the
formation of fenestrae in the human testis vasculature
[20]. As a result, they might contribute to the modulation
of the transport of testosterone out of the testis and of
regulatory factors into the testis [35]. Additionally, it has
been proposed that PKs potentially function as mediators
of the inflammatory response during testicular infections
[20]. This proposition is based on the fact that the testis is a
site of inflammation in response to bacterial and viral
infections [36,37], and that PKs have been implicated in
the evolution of innate and acquired immune responses
[25].www.sciencedirect.comThe expression of PKs and their receptors has been
reported in the prostate [1,14,38]. However, at the protein
level, PK1 expression has been detected only in hyperplas-
tic and cancerous tissue [38]. More studies are necessary to
evaluate whether PKs have a role in the normal and
diseased prostate.
Female reproductive function
PKs and their receptors are expressed in the ovary, uterus
and in various tissues of pregnancy [21,23,39]. In the
normal ovary, PK1 is expressed in a dynamic way in
elements of the sex cord–stroma lineage [40], whereas
PK2 expression is not detectable [21]. During follicle matu-
ration, PK1 and VEGF expression are inversely related. In
primordial and primary follicles, there is high expression of
PK1 in granulosa cells but no VEGF expression. Maturing
secondary follicles maintain strong PK1 expression and
weak to moderate VEGF expression. However, in the
antral follicle, PK1 is expressed at low levels in theca cells,
whereas VEGF expression is very strong in granulosa cells
and moderate in theca cells. In the mature atretic follicle,
PK1 expression is strong again in residual theca but VEGF
expression is weak [21]. In the corpus luteum, the mRNA
expression of PK1 increases as the corpus luteummatures,
whereas VEGF expression is already maximal at the early
luteal phase [21,22]. These different expression patterns
suggest that VEGF and PK1 have different roles in the
vasculature and/or non-vascular roles in the corpus
luteum. The actions of PK1 in the ovary are likely to be
mediated by PKR1 and PKR2, which are expressed in the
human ovary [14,16]. However, their precise localization
remains to be elucidated.
Studies in vitro suggest that PK1 has a role in the
proliferation and survival of endothelial cells of the bovine
corpus luteum [41]. Also, an indirect role in angiogenesis in
the corpus luteum has been suggested following the obser-
vation that PK1 can stimulate the expression of VEGF [42].
In the non-pregnant uterus, PK1 is expressed in the
glandular epithelium, as well as in the endothelial and
stromal cells of the endometrium, predominantly in the
functional layer [39]. It is also expressed in endothelial
cells and smooth muscle cells of the myometrium [39]. PK1
expression is dynamic across the menstrual cycle, with low
levels of expression during the early follicular phase, fol-
lowed by a gradual increase of expression that peaks at the
midluteal phase and finally a decrease in expression
during the late luteal phase [43] (Figure 3). PK2, PKR1
and PKR2 are also expressed in various cellular compart-
ments of the endometrium but they do not show a temporal
variation in their mRNA expression across the menstrual
cycle [39]. PK1 is expressed in endometrial tissue during
the reproductive age but no expression is detected after
menopause. This correlates with the fact that PK1 expres-
sion is hormonally modulated, with oestrogen and pro-
Figure 3. (a) Temporal expression of PK1 protein in human endometrium across the menstrual cycle. PK1 protein expression gradually rises from low levels during the
early proliferative stage to high levels that peak at the midluteal phase (window of implantation), followed by a decrease in expression in the late luteal phase [43]. This is a
result of PK1 being modulated by oestrogen and progesterone in the endometrium [39,43]. (b) PKs and their receptors are expressed in different cellular compartments of
the uterus. Hence, PKs have the potential to participate in multiple cellular processes. Arrows designate the potential autocrine and paracrine modes of action of PKs
through PKRs in the different cellular compartments of the endometrium.
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endometrium [39,43].
Further support for a role of PKs in reproductive func-
tion can be gleaned from PKR2 knockout mice, which show
hypoplasia of the reproductive tract [28]. This phenotype
has been explained by the lack of GnRH neurones in the
hypothalamus of these animals. However, it is possible
that the loss of a direct role of PKR2 in the reproductive
tract contributes to the observed atrophy of these tissues.
PK2 or PKR1 knockout mice do not show abnormalities in
the reproductive tract [28,30].
Potential role of PKs in pregnancy
Implantation
PK1, but not PK2, PKR1 or PKR2, expression peaks during
the midluteal ‘window of implantation’, with immunoloca-
lization to endometrial glandular epithelium, stromal and
endothelial cells, and myometrial vascular endothelium as
well as smooth muscle [39,43,44].
Hyperaemia and endothelial leakage at the implantation
site are one of the earliest signs of implantation [45,46]. It
hasbeenhypothesized that, by inducing fenestrae formation
and increasing microvascular permeability, PK1 might be
involved in effecting this hyperpermeability, thereby facil-
itating implantation [39,43]. More studies are required to
evaluate whether PKs are involved in perimplantation
spiral arteriole formation and recruitment of immune cells,
including uterine natural killer cells, which have been
shown to increase in number during the implantation win-
dow and early pregnancy [47].
PKs and the fetoplacental unit
The expression of PK1 and PKR1 peaks in the trophoblast
between 8–10 weeks of gestation, with PK1 being localizedwww.sciencedirect.comto the syncytiotrophoblast, minimal expression in the
cytotrophoblast and no expression in the extravillous
trophoblast [23]. This contrasts with VEGF and its recep-
tors, which are predominantly expressed in the extravil-
lous trophoblast and cytotrophoblast [23,48,49]. However,
VEGF and PK1 are both expressed from six weeks of
gestation in fetal Hofbauer cells in placental villous
mesenchyme. PK2 and PKR2 are not expressed in first
trimester trophoblasts, apart from between 8–10 weeks of
gestation, when low levels of expression are detected.
Expression of PKR2 in fetal vascular endothelial cells rises
after 12 weeks of gestation [23]. Although expression of
PK1 and PK2, the latter at considerably lower levels, has
been demonstrated in third trimester placentae, neither
cellular localization nor receptor expression has been stu-
died [2,6,20,50]. Similarly, no studies have investigated
the expression of PKs or their receptors in first trimester
decidua or myometrium, or in the second trimester
fetoplacental unit.
It has been proposed that PK1 and PKR1 have an
important role in placentation, owing to their expression
peaking during the crucial hypoxic period of placentation
(8th–10th week) before establishment of the haemochorial
circulation [23]. Hypoxic regulation of PK1 and PKR1 is
supported by the presence of a hypoxia-inducible factor
(HIF-1a) binding site in the promoter of both PK1 and
PKR1. However, factors such as human chorionic gonado-
tropin [43] and progesterone [39], which are known to
regulate PK1 expression, are also expressed during this
period and they might therefore participate in PK1 regu-
lation. The strong expression of PK1 by the syncytiotro-
phoblast, which is the endocrine component of the
placenta, suggests that PK1 expression might be associ-
ated with a degree of trophoblast differentiation, and it has
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growth factor [23]. More studies are required to evaluate
whether PKs are involved in fetal haematopoiesis, immune
cell trafficking, maintenance of syncytial integrity and
myometrial contractility.
Role of PKs in pathologies of the reproductive tract
Several studies suggest that PKs have a role in
pathological conditions of the reproductive tract. In the
male, Samson et al. [35] demonstrated that PK1 is
expressed in Leydig cell neoplasms. The increased micro-
vasculature observed in these types of tumour compared
with other types of testicular cancer, such as seminoma,
suggest that PK1 has a role in Leydig cell tumour growth
by promoting angiogenesis [35]. Also, PK1 is localized, at
low levels, in glandular epithelial cells and hyperplastic
benign prostate tissue, and increasing levels are detected
in prostate cancer as the disease progresses [38]. These
data suggest that PK1 could have an important role in
Leydig cell tumours and prostate cancer, and could there-
fore be used as a marker for disease progression. In pros-
tate cancer, increased mRNA expression of PK2 is also
observed in malignant epithelial cells compared with nor-
mal epithelium, suggesting that both PKs might have a
role in this pathology [38].
A direct role for PKs in cancers of the female
reproductive tract has not been ascertained. In
endometrial and ovarian carcinoma, it has been shown
that PK1 expression is either absent or reduced compared
with normal tissue [40,43]. However, a putative role for
PK1 in the evolution of ovarian carcinoma has been
suggested from the observation that this factor is
expressed in non-tumour stromal cells and tumour-infil-
trating T lymphocytes in this carcinoma [40].
Hyperplasia and hypervascularity of the stroma are key
features in the development of polycystic ovarian
syndrome (PCOS). The search for factors responsible for
these features has identified strong expression of VEGF
and PK1 in PCOS [21]. Strong correlation between PK1
expression and hyperplasia and angiogenesis has been
reported, suggesting that PK1 could have a role in the
development of this pathology [21]. Such a role is further
supported by observations that adenoviral delivery of PKs
to rat ovaries results in a phenotype similar to PCOS [2]. In
addition, it has been suggested that PK1 could have a role,
together with VEGF [51], in mediating the dysregulated
vascular permeability that occurs in ovarian hyperstimu-
lation syndrome [21].
In preeclampsia, the underlying pathophysiology
remains unclear but the resulting placenta is relatively
hypoxic, with evidence of chronic inflammatory and vaso-
occlusive lesions. A study by Chung et al. [50] reported no
difference in PK1 expression in third trimester placentae
from either preeclamptic or normal pregnancies. However,
increasing evidence suggests that the origin of preeclamp-
sia is in the first trimester, with deficient adaptation
between the maternal vascular system and fetoplacental
unit. Changes in protein expression after disease onset are
considered to be the consequence, rather than the cause, of
its development. It has therefore been suggested that
PK1 and PKR1 might have a role in the development ofwww.sciencedirect.compreeclampsia, given their temporal expression during the
crucial hypoxic period of placentation during the first
trimester [23].
Summary
The diverse spectrum of established and potential
regulatory functions of PKs in the nervous, immune,
haematopoietic, vascular, gastrointestinal and reproduc-
tive systems suggest that they will be the targets of drug
development for numerous pathologies. Within the repro-
ductive system, they are expressed in the testis, prostate,
ovary, uterus, placenta and neurones regulating GnRH
neuronal development. The last of these is the only estab-
lished function, and substantial experimental research is
needed to complement the observational studies in this
emerging arena, to establish functions in reproductive
tissues. The development of immunoneutralizing anti-
bodies and small-molecule antagonist and agonist
analogues of these complex proteins will greatly enhance
the elucidation of their functions, with the promise of
establishing therapeutic interventions in reproductive
pathologies. Such molecules will also aid in the dissection
of the relative contribution of each of the PKs and their
receptors to reproductive physiology and pathology. More-
over, future research aimed at the development of targeted
and tissue-specific knockout of the genes encoding each of
these proteins in mice will help to elucidate their specific
role in reproductive function.
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